According to a report from Coherent Market Insights, the global coagulation analyzers market that was valued at US$ 2,481.7 million in 2017, is expected to exhibit a CAGR of 9.7% over the forecast period (2017-2025) and reach US$ 13.17B by 2025.
Introduction of new coagulation analyzers by manufacturers is a key factor that is expected to boost growth of the market. For example, in 2015, Instrumentation Laboratory launched the ACL TOP Family 50 series for mid- to high-volume clinical laboratories for routine to specialty assays, including clotting, chromogenic, and immunological assays. Other key factors that are driving the market's growth include
- Increasing adoption of handheld coagulation analyzers by clinical laboratories, which provides accurate results in low turnaround time
- Rising prevalence of heart diseases such as atrial fibrillation and blood disorders
- Increasing geriatric population that increased the demand for coagulation testing that facilitates rapid interventions
- Reduction in the size of coagulation analyzers, which has led to increasing adoption of these in ambulatory surgical centers and
- Reduction in turnaround time facilitated by coagulation analyzers
Increasing demand for testing reagents and kits by hospitals and other centers for diagnosis is also expected to be the major factor responsible for the largest market share of consumables in this market.
Key players in the global coagulation analyzer market includes Siemens AG, Thermo Fisher Scientific Inc., Hoffmann-La Roche Ltd., Instrumentation Laboratory, Sysmex Corporation, Beckman Coulter, Inc. (Danaher), Diamond Diagnostics, International Technidyne Corporation, Nihon Kohden Corporation, and Alere Inc.
Most of these manufacturers are focusing on developing innovative diagnostic tools to improve the speed of diagnosis for patients suffering from various diseases, mainly in the emergency departments, which would allow treatments to be started earlier and also help prevent further risks associated with these conditions.